![]() The CRT decreased significantly after both treatments (mean CRT before SML: 445☑53 μm, after SML: 297☙5, Po0.001 mean CRT before PDT: 398☘8 μm, after PDT: 322☙3 μm, Po0.001, Wilcoxon’s signed-rank test). Results: Patients showed treatment response more often in the SML group compared with the PDT group (treatment response after SML: 33 eyes (79%), PDT: 34 eyes (59%), P=0.036, χ2 test). The treatment success was evaluated 6 weeks after treatment using best-corrected visual acuity, central retinal thickness, and resolution of SRF in spectral domain optical coherence tomography. The treatment was applied at the leakage sites in the fluorescein and indocyanine green angiography. Methods: This retrospective study included 100 eyes of 100 consecutive patients who were treated with the 577 nm SML (Supra Scan, Quantel Medical) (n=42) or half-dose PDT (n=58) for cCSC. Purpose: To compare the short-term treatment outcome of the 577 nm subthreshold micropulse laser (SML) and half-dose photodynamic therapy (PDT) in patients with chronic central serous chorioretinopathy (cCSC) and persistent subretinal fluid (SRF). A history of psychiatric illness is associated with an increased risk of CSC recurrence. ![]() Multivariate Cox regression analysis showed that patients with a history of psychiatric illness (adjustment disorder and depression) were associated with an increased risk of CSC recurrence (hazard ratio = 3.5, p = 0.011).Ĭonclusions: The long-term visual prognosis of CSC is fair without treatment, and a significant proportion of patients developed recurrence of CSC. During follow-up, 38 (52.1%) patients experienced ≥1 episode of CSC recurrence. At the last follow-up, 9 (12.3%) eyes showed improved vision of ≥2 lines, and 12 (16.4%) showed a worsening of ≥2 lines. The difference between the final and baseline BCVAs was not statistically significant (p = 0.79). After a mean follow-up of 72 months, the mean final logMAR BCVA was 0.32. At baseline, the mean logMAR best corrected visual acuity (BCVA) was 0.30. Results: Seventy-three eyes of 73 patients were included, and the mean age was 44.6 years. Patient demographics, visual outcome and risk factors for the recurrence of CSC were analyzed. Methods: Retrospective review of untreated CSC patients with a follow-up of ≥3 years. Yellow 577nm SubLiminal ® laser therapy seems to be a promising alternative treatment strategy 8.īackground: To evaluate risk factors for the recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy (CSC).PDT laser therapy can also be used, however, even when using reduced treatment settings it has also number of side effects such as RPE atrophy, choroidal neovascularization, choriocapillaris ischemia, and transient reduction of macular function. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |